The Tumor Microenvironment State Associates with Response to HPV Therapeutic Vaccination in Patients with Respiratory Papillomatosis

A first-in-human, Phase I study of adjuvant PRGN-2012 treatment in adult patients with severe, aggressive recurrent respiratory papillomatosis demonstrated the overall safety and clinically meaningful benefit observed with PRGN-2012, with a 50% complete response rate in patients treated at the highest dose.